Influenza Vaccine

29 registered clinical trials studyying Influenza Vaccine — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older NCT07421050	Ab&B Bio-tech Co., Ltd.JS	Phase 1
Active Not Recruiting	Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Ol NCT07421037	Ab&B Bio-tech Co., Ltd.JS	Phase 1
Not Yet Recruiting	Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccine Uptake Among Healthcare Workers NCT07157163	Centers for Disease Control and Prevention, China	N/A
Completed	Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate NCT06646406	Mayo Clinic	N/A
Completed	Influenza Vaccine Elicited Immune Response in Immunocompromised Patients NCT06738082	Insel Gruppe AG, University Hospital Bern	—
Completed	Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vac NCT06987942	Sinovac (Dalian) Vaccine Technology Co., Ltd.	Phase 4
Completed	Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older NCT07332689	Ab&B Bio-tech Co., Ltd.JS	—
Unknown	Cost-effectiveness of the Influenza Vaccination NCT05996549	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 4
Recruiting	A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults NCT05518500	The Jackson Laboratory	Phase 4
Completed	Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Olde NCT05163847	FluGen Inc	Phase 1
Completed	Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination NCT05157425	AB Biotics, SA	N/A
Completed	Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years NCT04785794	FluGen Inc	Phase 1
Unknown	Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients NCT05070494	Mahidol University	Phase 4
Completed	Influenza 2020/2021 NCT04546854	University of Warwick	N/A
Unknown	Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors NCT04355806	Shanghai Pulmonary Hospital, Shanghai, China	—
Unknown	Influenza Vaccine in Children With Asthma NCT04086628	Central Hospital, Nancy, France	—
Completed	Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome NCT06304038	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Unknown	A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age NCT03285997	Green Cross Corporation	Phase 3
Unknown	Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - NCT03399357	Tan Tock Seng Hospital	—
Completed	Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Beha NCT04230343	SB Istanbul Education and Research Hospital	N/A
Completed	Imiquimod and Influenza Vaccine for Immunocompromised Patients NCT02960815	University of Lausanne Hospitals	Phase 2
Completed	Immunogenicity of H5N1 Vaccine Following H5N2 NCT02153671	PATH	Phase 2
Completed	Efficacy and Safety of Influenza Vaccine During Sarcoidosis NCT01687517	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Comparison of 4 Influenza Vaccines in Seniors NCT01368796	University of British Columbia	Phase 4
Completed	Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients NCT01180699	University of Alberta	N/A
Completed	Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting NCT00828555	Duke University	—
Completed	Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients NCT00760175	University of Alberta	N/A
Completed	Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine NCT00542776	Boston Children's Hospital	—
Completed	A Phase 2 Study to Evaluate Immune Responses of FluMist® NCT00461981	MedImmune LLC	Phase 2